Implanted depleted uranium fragments cause soft tissue sarcomas in the muscles of rats.
In this study, we determined the carcinogenicity of depleted uranium (DU) metal fragments containing 0.75% titanium in muscle tissues of rats. The results have important implications for the medical management of Gulf War veterans who were wounded with DU fragments and who retain fragments in their soft tissues. We compared the tissue reactions in rats to the carcinogenicity of a tantalum metal (Ta), as a negative foreign-body control, and to a colloidal suspension of radioactive thorium dioxide ((232)Th), Thorotrast, as a positive radioactive control. DU was surgically implanted in the thigh muscles of male Wistar rats as four squares (2.5 x 2.5 x 1.5 mm or 5.0 x 5.0 x 1.5 mm) or four pellets (2.0 x 1.0 mm diameter) per rat. Ta was similarly implanted as four squares (5.0 x 5.0 x 1.1 mm) per rat. Thorotrast was injected at two sites in the thigh muscles of each rat. Control rats had only a surgical implantation procedure. Each treatment group included 50 rats. A connective tissue capsule formed around the metal implants, but not around the Thorotrast. Radiographs demonstrated corrosion of the DU implants shortly after implantation. At later times, rarifactions in the radiographic profiles correlated with proliferative tissue responses. After lifetime observation, the incidence of soft tissue sarcomas increased significantly around the 5.0 x 5.0 mm squares of DU and the positive control, Thorotrast. A slightly increased incidence occurred in rats implanted with the 2.5 x 2.5 mm DU squares and with 5.0 x 5.0 mm squares of Ta. No tumors were seen in rats with 2.0 x 1.0 mm diameter DU pellets or in the surgical controls. These results indicate that DU fragments of sufficient size cause localized proliferative reactions and soft tissue sarcomas that can be detected with radiography in the muscles of rats.
Hahn
Fletcher F
FF
Lovelace Respiratory Research Institute, Albuquerque, New Mexico 87108, USA. fhahn@lrri.org
Guilmette
Raymond A
RA
Hoover
Mark D
MD
D000818:Animals; D001681:Biological Assay; D002273:Carcinogens / Q000008:administration & dosage / Q000009:adverse effects*; D002455:Cell Division; D002471:Cell Transformation, Neoplastic; D005547:Foreign Bodies; D006801:Humans; D008297:Male; D010316:Particle Size; D051381:Rats; D017208:Rats, Wistar; D012509:Sarcoma / Q000139:chemically induced* / Q000662:veterinary; D012983:Soft Tissue Neoplasms / Q000139:chemically induced* / Q000662:veterinary; D013911:Thorium Dioxide / Q000008:administration & dosage / Q000009:adverse effects*; D014501:Uranium / Q000008:administration & dosage / Q000009:adverse effects* / Q000737:chemistry; D014728:Veterans
D002273:Carcinogens; D014501:Uranium; D013911:Thorium Dioxide